當(dāng)前位置：首頁(yè) JCRQ1 期刊介紹(非官網(wǎng))

BloodSCIE

國(guó)際簡(jiǎn)稱：BLOOD 參考譯名：血液

中科院分區(qū)
1區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：0006-4971; E-ISSN：1528-0020; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：是

出版信息：: 出版地區(qū)：UNITED STATES; 出版商：American Society of Hematology; 出版語(yǔ)言：English; 出版周期：Semimonthly; 出版年份：1946; 研究方向：醫(yī)學(xué)-血液學(xué)

評(píng)價(jià)信息：: 影響因子：21; H-index：426; CiteScore指數(shù)：23.6; SJR指數(shù)：5.272; SNIP指數(shù)：3.149

發(fā)文數(shù)據(jù)：: Gold OA文章占比：26.77%; 研究類文章占比：86.54%; 年發(fā)文量：379; 自引率：0.0394...; 開源占比：0.1201; 出版撤稿占比：0; 出版國(guó)人文章占比：0.04; OA被引用占比：0.0086...

投稿咨詢加急見(jiàn)刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見(jiàn)問(wèn)題

英文簡(jiǎn)介Blood期刊介紹

Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on the originality and importance of the observations or investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well organized and clearly written. Authors submit a manuscript with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and is not currently submitted elsewhere for print or electronic publication.

Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate. Authors are invited to contact the Editor-in-Chief prior to submission if they are uncertain whether their work falls within the general scope of the journal.

期刊簡(jiǎn)介Blood期刊介紹

《Blood》自1946出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見(jiàn)解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：約1.0個(gè)月
國(guó)際TOP期刊
醫(yī)學(xué)
HEMATOLOGY
SCIE
中科院1區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Blood Cite Score數(shù)據(jù)

CiteScore：23.6
SJR：5.272
SNIP：3.149

學(xué)科類別	分區(qū)	排名	百分位
大類：Biochemistry, Genetics and Molecular Biology 小類：Biochemistry	Q1	11 / 438	97%
大類：Biochemistry, Genetics and Molecular Biology 小類：Hematology	Q1	6 / 137	95%
大類：Biochemistry, Genetics and Molecular Biology 小類：Cell Biology	Q1	18 / 285	93%
大類：Biochemistry, Genetics and Molecular Biology 小類：Immunology	Q1	18 / 236	92%

CiteScore 是由Elsevier(愛(ài)思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過(guò)影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Blood 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：是

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	1區(qū)	HEMATOLOGY 血液學(xué)	1區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Blood JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：HEMATOLOGY	SCIE	Q1	2 / 97	98.5%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：HEMATOLOGY	SCIE	Q1	4 / 97	96.39%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問(wèn)題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
USA8482
GERMANY (FED REP GER)1473
Italy1246
England1245
France1110
CHINA MAINLAND1016
Canada958
Japan760
Spain669
Netherlands619

本刊中國(guó)學(xué)者近年發(fā)表論文

1、PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371
Author: Chen, Hongxia; Bai, Yunpeng; Kobayashi, Michihiro; Xiao, Shiyu; Cai, Wenjie; Barajas, Sergio; Chen, Sisi; Miao, Jinmin; Meke, Frederick Nguele; Vemula, Sasidhar; Ropa, James P.; Croop, James M.; Boswell, H. Scott; Wan, Jun; Jia, Yuzhi; Liu, Huiping; Li, Loretta S.; Altman, Jessica K.; Eklund, Elizabeth A.; Ji, Peng; Tong, Wei; Band, Hamid; Huang, Danny T.; Platanias, Leonidas C.; Zhang, Zhong-Yin; Liu, Yan

Journal: BLOOD. 2023; Vol. 141, Issue 3, pp. 244-259. DOI: 10.1182/blood.2022016580
2、Human genetic defects in SRP19 and SRPRA cause severe congenital neutropenia with distinctive proteome changes
Author: Linder, Monika I.; Mizoguchi, Yoko; Hesse, Sebastian; Csaba, Gergely; Tatematsu, Megumi; Lyszkiewicz, Marcin; Zietara, Natalia; Jeske, Tim; Hastreiter, Maximilian; Rohlfs, Meino; Liu, Yanshan; Grabowski, Piotr; Ahomaa, Kaarin; Maier-Begandt, Daniela; Schwestka, Marko; Pazhakh, Vahid; Isiaku, Abdulsalam I.; Miranda, Brenda Briones; Blombery, Piers; Saito, Megumu K.; Rusha, Ejona; Alizadeh, Zahra; Pourpak, Zahra; Kobayashi, Masao; Rezaei, Nima; Unal, Ekrem; Hauck, Fabian; Drukker, Micha; Walzog, Barbara; Rappsilber, Juri; Zimmer, Ralf; Lieschke, Graham J.; Klein, Christoph

Journal: BLOOD. 2023; Vol. 141, Issue 6, pp. 645-658. DOI: 10.1182/blood.2022016783
3、C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse
Author: Yang, Li-Xue; Zhang, Cheng-Tao; Yang, Meng-Ying; Zhang, Xue-Hong; Liu, Hong-Chen; Luo, Chen -Hui; Jiang, Yue; Wang, Zhang-Man; Yang, Zhong-Yin; Shi, Zhao -Peng; Yang, Yi-Ci; Wei, Ruo-Qu; Zhou, Li; Mi, Jun; Zhou, Ai -Wu; Yao, Zhi-Rong; Xia, Li; Yan, Jin-Song; Lu, Ying

Journal: BLOOD. 2023; Vol. 141, Issue 7, pp. 766-786. DOI: 10.1182/blood.2022017046.
4、Cloned antibodies from patients with HIT provide new clues to HIT pathogenesis
Author: Zhu, Wen; Zheng, Yongwei; Yu, Mei; Wu, Yaling; Wei, Jianhui; Zhou, Lu; Fu, Guoping; Schneider, Nicholas; Jones, Curtis; Irani, Mehraboon; Padmanabhan, Anand; Aster, Richard; Wang, Demin; Wen, Renren

Journal: BLOOD. 2023; Vol. 141, Issue 9, pp. 1060-1069. DOI: 10.1182/blood.2022017612
5、A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis
Author: Yu, Xiaoliang; Ma, Haikuo; Li, Bohan; Ji, Yuting; Du, Yayun; Liu, Siying; Li, Zhanhui; Hao, Yongjin; Tian, Sheng; Zhao, Cong; Du, Qian; Jin, Zhongqin; Zhu, Xueming; Tian, Yuanyuan; Chen, Xin; Sun, Xue; Yang, Chengkui; Zhu, Fang; Ju, Jie; Zheng, Yunjing; Zhang, Wei; Wang, Jingrui; Yang, Tao; Wang, Xinhui; Li, Jingjing; Xu, Xiangping; Du, Shujing; Lu, Haohao; Ma, Feng; Zhang, Haibing; Zhang, Yi; Zhang, Xiaohu; Hu, Shaoyan; He, Sudan

Journal: BLOOD. 2023; Vol. 141, Issue 9, pp. 1070-1086. DOI: 10.1182/blood.2022017262
6、Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation
Author: Zeng, Xiangjun; Li, Xiaoqing; Li, Xia; Wei, Cong; Shi, Ce; Hu, Kejia; Kong, Delin; Luo, Qian; Xu, Yulin; Shan, Wei; Zhang, Meng; Shi, Jimin; Feng, Jingjing; Han, Yingli; Huang, He; Qian, Pengxu

Journal: BLOOD. 2023; Vol. 141, Issue 14, pp. 1691-1707. DOI: 10.1182/blood.2022017514
7、Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Author: Kusumoto S¹, Arcaini L^2,³, Hong X⁴, Jin J⁵, Kim WS⁶, Kwong YL⁷, Peters MG⁸, Tanaka Y⁹, Zelenetz AD^10,¹¹, Kuriki H¹², Fingerle-Rowson G¹³, Nielsen T¹³, Ueda E¹², Piper-Lepoutre H¹³, Sellam G¹³, Tobinai K¹⁴.

Journal: Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.
8、The transmembrane protein disulfide isomerase TMX1 negatively regulates platelet responses.
Author: Zhao Z¹, Wu Y^1,², Zhou J^1,², Chen F¹, Yang A¹, Essex DW².

Journal: Blood. 2019 Jan 17;133(3):246-251. doi: 10.1182/blood-2018-04-844480. Epub 2018 Nov 13.